Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study

These are the supplementary materials associated with the manuscript submitted to the Journal of the American Academy of Dermatology entitled “Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study”. The files include supplementary methods describing the treatment protocol, study population, and statistical analysis, a supplementary table reporting the multivariable generalized linear mixed model analysis of predictors of long-term treatment success, and a supplementary figure illustrating the study design and treatment assessment timeline. These materials provide additional methodological details and supporting analyses referenced in the main manuscript.本材料为提交至《美国皮肤病学会杂志（Journal of the American Academy of Dermatology）》、题为《古塞库单抗（guselkumab）早期应答与未使用过生物制剂（biologic-naïve）状态可预测轻中度斑块状银屑病延长给药间隔的持续疗效：一项真实世界回顾性研究》的论文的附属材料。所包含的文件包括：详述治疗方案、研究人群与统计学分析方法的补充方法学内容；报告长期治疗成功预测因子多变量广义线性混合模型（multivariable generalized linear mixed model）分析结果的补充表格；以及阐释研究设计与治疗评估时间线的补充插图。本套附属材料提供了正文中引用的额外方法学细节与支持性分析结果。